Novozymes Receivables 2011-2024 | NVZMY

Novozymes receivables for the quarter ending June 30, 2024 were $0.621B, a 5.27% increase year-over-year.

  • Novozymes receivables for 2024 were $0.909B, a 46.3% increase from 2023.
  • Novozymes receivables for 2023 were $0.621B, a 5.27% increase from 2022.
  • Novozymes receivables for 2022 were $0.59B, a 1.21% decline from 2021.

Novozymes Receivables 2011-2024 | NVZMY

  • Novozymes receivables for 2024 were $0.909B, a 46.3% increase from 2023.
  • Novozymes receivables for 2023 were $0.621B, a 5.27% increase from 2022.
  • Novozymes receivables for 2022 were $0.59B, a 1.21% decline from 2021.
Related Stocks
Company NameMarket
Cap
Linde (LIN)$213.8B
Sherwin-Williams (SHW)$83.8B
Ecolab (ECL)$67.7B
Givaudan SA (GVDNY)$42.9B
SIKA AG - (SXYAY)$38.3B
PPG Industries (PPG)$22.7B
International Flavors & Fragrances (IFF)$18.5B
Symrise AG (SYIEY)$15.1B
RPM (RPM)$13.2B
Toray Industries (TRYIY)$10.3B
Sociedad Quimica Y Minera S.A (SQM)$10B
Axalta Coating Systems (AXTA)$6.8B
FUCHS SE - (FUPBY)$6.6B
NewMarket (NEU)$5.4B
Balchem (BCPC)$5.3B
CSW Industrials (CSWI)$5B
Croda (COIHY)$5B
Element Solutions (ESI)$4.6B
Celanese (CE)$4.4B
Nissan Chemical (NNCHY)$4.3B
Sensient Technologies (SXT)$3.2B
H B Fuller (FUL)$2.9B
Hawkins (HWKN)$2.5B
Ashland (ASH)$2.4B
Minerals Technologies (MTX)$1.8B
Quaker Houghton (KWR)$1.8B
Perimeter Solutions, SA (PRM)$1.5B
Orbia Advance, S.A.B De C.V (MXCHY)$1.4B
Ingevity (NGVT)$1.2B
ELEMENTIS (ELMTY)$1.1B